Drug
Avp 21d9
Avp 21d9: highest development phase Phase 1, developed by Emergent BioSolutions. 1 trial record tracked on RxWires.
- Highest phase
- Phase 1
- Developer
- Emergent BioSolutions
Trials
| Drug | Phase | Indication |
|---|---|---|
| AVP-21D9 NCT01202695 | Phase 1 | Anthrax |
Latest
No recent events.
Follow Avp 21d9 on RxWires to get trial status changes, FDA actions, filings and patent dates as they happen.
Sourced from ClinicalTrials.gov, openFDA, SEC EDGAR and the FDA Orange Book. Not investment or medical advice.